Skip to main content
. 2020 May 12;9(5):1441. doi: 10.3390/jcm9051441

Figure 2.

Figure 2

Cancer-specific survival in all patients included (n = 155): Impact of pre-treatment Neutrophil-to-Lymphocyte (NLR; cut-off ≥ 2.2), Systemic Immune-Inflammatory Index (SII ≥ 1100), Monocyte-to-Lymphocyte Ratio (MLR; ≥0.18), and circulating lymphocytes (<1.0 × 109/L) on cancer-specific survival (CSS) of the of the endometrial cancer (EC) patients.